Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific EnolaseEnzyme Immunoassay
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378869523 | ||
| 003 | CHVBK | ||
| 005 | 20180305123406.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030127xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.017 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.017 | ||
| 245 | 0 | 0 | |a Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific EnolaseEnzyme Immunoassay |h [Elektronische Daten] |c [Thomas Muley, Werner Ebert, Petra Stieber, Hannelore Raith, Stefan Holdenrieder, Dorothea Nagel, Heinrich Fürst, Hans-Jürgen Roth, Hilmar Luthe, Bert G. Blijenberg, Eberhard Gurr, Wolfgang Uhl, Joachim von Pawel, Peter Drings] |
| 520 | 3 | |a This international multicenter study was designed to evaluate the technical performance of the new double-monoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test for the diagnosis of small-cell lung cancer (SCLC). Intra- and inter-assay coefficients of variation, determined in five control or serum specimens in six laboratories, ranged from 0.7 to 5.3 (inter-laboratory median: 1.3%) and from 1.3 to 8.5 (inter-laboratory median: 3.4%), respectively. Laboratory-to-laboratory comparability was excellent with respect to recovery and inter-assay coefficients of variation. The test was linear between 0.0 and 320 ng/ml (highest measured concentration). There was a significant correlation between NSE concentrations measured using the Elecsys NSE and the established Cobas Core NSE EIA II in all subjects (n = 723) and in patients with lung cancer (n = 333). However, NSE concentrations were systematically lower (approximately 9%) with the Elecsys NSE than with the comparison test. Based on a specificity of 95% in comparison with the group suffering from benign lung diseases (n = 183), the cut-off value for the discrimination between malignant and benign conditions was set at 21.6 ng/ml. NSE was raised in 73.4% of SCLC patients (n = 188) and was significantly higher (p < 0.01) in extensive (87.8%) as opposed to limited disease (56.7%). NSE was also elevated in 16.0% of the cases with nonsmall cell lung cancer (NSCLC, n = 374). It is concluded that the Elecsys NSE EIA is a reliable and accurate diagnostic procedure for the measurement of NSE in serum samples. The special merits of this new assay are the wide measuring range (according to manufacturer's declaration up to 370 ng/ml) and a short incubation time of 18 min. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Muley |D Thomas |4 aut | |
| 700 | 1 | |a Ebert |D Werner |4 aut | |
| 700 | 1 | |a Stieber |D Petra |4 aut | |
| 700 | 1 | |a Raith |D Hannelore |4 aut | |
| 700 | 1 | |a Holdenrieder |D Stefan |4 aut | |
| 700 | 1 | |a Nagel |D Dorothea |4 aut | |
| 700 | 1 | |a Fürst |D Heinrich |4 aut | |
| 700 | 1 | |a Roth |D Hans-Jürgen |4 aut | |
| 700 | 1 | |a Luthe |D Hilmar |4 aut | |
| 700 | 1 | |a Blijenberg |D Bert G. |4 aut | |
| 700 | 1 | |a Gurr |D Eberhard |4 aut | |
| 700 | 1 | |a Uhl |D Wolfgang |4 aut | |
| 700 | 1 | |a von Pawel |D Joachim |4 aut | |
| 700 | 1 | |a Drings |D Peter |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/1(2003-01-27), 95-103 |x 1434-6621 |q 41:1<95 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.017 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.017 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Muley |D Thomas |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ebert |D Werner |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Stieber |D Petra |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Raith |D Hannelore |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Holdenrieder |D Stefan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nagel |D Dorothea |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fürst |D Heinrich |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Roth |D Hans-Jürgen |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Luthe |D Hilmar |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Blijenberg |D Bert G. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gurr |D Eberhard |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Uhl |D Wolfgang |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a von Pawel |D Joachim |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Drings |D Peter |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/1(2003-01-27), 95-103 |x 1434-6621 |q 41:1<95 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||